Dr. Reddy's Labs News and Updates

Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 3
Author: Motilal Oswal

Keep track of all breaking news on Dr. Reddy's Labs from all sources in a single place.

Load latest

Dr. Reddy's Laboratories Ltd.

25 Oct 2025

1280.60

0.10%

Earnings steady despite US pressure

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

Dr Reddy’s Labs (DRRD) delivered slightly better-than-expected revenue/EBITDA (3%/5% beat) in 2QFY26. Higher other income and a lower tax rate led to a 14% beat in PAT.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Oct 2025

1280.60

0.10%

Dr Reddy's Q2 net profit up 14% despite slump in North America biz

Business Standard

For H1FY26, profit after tax rose 8 per cent Y-o-Y and revenue grew 11 per cent, led by branded markets and contributions from the Nicotine Replacement Therapy (NRT) portfolio

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr Reddy's Q2 Results: Profit Rises 7% On Sharp Climb In Europe Business

NDTV Profit | 24 Oct 2025 3 more

Dr. Reddy's Laboratories Ltd.

24 Oct 2025

1280.60

0.10%

to see Rapid results content

Dr. Reddy's Laboratories Ltd.

23 Oct 2025

1280.60

0.10%

Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates

Business Standard

Dr Reddy's net profit is expected to come at 1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against 1,401 crore in the year-ago period

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

21 Oct 2025

1280.60

0.10%

USFDA says 'voluntary action' required at Dr Reddy's Srikakulam unit

Business Standard

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulator for its formulations manufacturing facility at Srikakulam in Andhra Pradesh, classifying the facility as voluntary action indicated. The US Food & Drug Administration (USFDA) had conducted a GMP and a Pre-Approval Inspection (PAI) conducted by at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, India, intimated to the exchanges on July 18, 2025, Dr Reddy's Laboratories Ltd said in a regulatory filing. "We wish to inform you that the company has received the Establishment Inspection Report (EIR) on October 20, 2025. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)'," it said, adding the inspection is officially closed. Under voluntary action indicated (VAI), while objectionable conditions were found and documented during an inspection, the agency is not prepared to take or...

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

19 Oct 2025

1280.60

0.10%

Glenmark, Dr Reddy's recall products in US over manufacturing issues: USFDA

Business Standard

Drugmakers Glenmark and Dr Reddy's Laboratories are recalling products in the US due to manufacturing issues, according to the US Food and Drug Administration (USFDA). As per its latest Enforcement Report, the US health regulator noted that a US-based unit of Glenmark Pharmaceuticals is recalling 26,928 packs of oral contraceptive medication in the US. Mahwah, New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the affected lot of Viorele, Desogestrel and Ethinyl Estradiol (USP, 0.15 mg/ 0.02 mg) and Ethinyl Estradiol tablets due to "failed impurities/degradation specifications." The affected lot was produced at Mumbai-headquartered drug maker's Goa manufacturing facility. The drug firm issued the Class II nationwide recall on September 3, 2025. USFDA stated that a US-based subsidiary of Dr Reddy's Laboratories is recalling the medication used to provide muscle relaxation during surgery. Princeton, New Jersey-based Dr. Reddy's Laboratories, Inc is recalling 571 vials o

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

19 Oct 2025

1280.60

0.10%

Glenmark, Dr Reddy's recall drugs in US over quality issues: USFDA

Business Line

USFDA cites impurities and stability failures in batches made at Indian facilities; both recalls classified as Class II.

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

12 Oct 2025

1280.60

0.10%

Dr Reddy's, Zydus recall drugs in US over manufacturing issues: USFDA

Business Line

Princeton-based Dr Reddy's Laboratories, Inc is recalling the affected lot of Succinylcholine Chloride Injection due to "Out-of-Specification result during the six-month stability testing," the USFDA stated